The end of May short selling can now be accessed from NASDAQ. Interestingly enough, short sellers at the end of May lightened up almost across the board on major NASDAQ biotech stocks from May 15 to May 30:
| STOCK (Ticker) | MAY 30 | MAY 15 | CHANGE |
| Amgen Inc. (NASDAQ: AMGN) | 22,678,517 | 24,778,770 | -8.48% |
| Biogen Idec Inc. (NASDAQ: BIIB) | 6,346,464 | 6,788,432 | -6.51% |
| Celgene Corporation (NASDAQ: CELG) | 13,775,373 | 16,336,232 | -15.68% |
| Gilead Sciences, Inc. (NASDAQ: GILD) | 32,478,444 | 32,690,603 | -0.65% |
| ImClone Systems Inc. (NASDAQ: IMCL) | 7,149,395 | 7,664,009 | -6.71% |
From the major names, a change in the overall trend can be spotted.
You can see the full short selling report for biotechs at BioHealthinvestor.com to see which other biotechs had an increase in short selling and to also see what the more active biotechs with lower market caps saw in their short selling activity.
Closing Bell: Can't go up every day (BAC, HE, HPW, COMS, BRCD, WMT, AMD)
Wal-Mart grows profit and cash flow in Q3, but comps still ailing
Chasing Value: Ten stocks for 2010 -- Part 2
